Company news

Kura Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kura Oncology Reports Second Quarter 2025 Financial Results

August 6, 2025

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

August 6, 2025

Kura Oncology to Report Second Quarter 2025 Financial Results

July 30, 2025

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

June 11, 2025

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

June 1, 2025

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 31, 2025

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 21, 2025

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 13, 2025

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 5, 2025

Kura Oncology Reports First Quarter 2025 Financial Results

April 30, 2025

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

April 27, 2025

Kura Oncology to Report First Quarter 2025 Financial Results

April 23, 2025

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

April 7, 2025

Kura Oncology to Participate in Stifel Targeted Oncology Forum

March 31, 2025

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

March 25, 2025

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

February 25, 2025

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

February 18, 2025

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

February 4, 2025

Kura Oncology Announces Senior Executive Promotions

January 5, 2025

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

December 8, 2024

Kura Oncology to Host Virtual Investor Event on December 9, 2024

December 1, 2024

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

November 24, 2024

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

November 19, 2024

Kura Oncology Reports Third Quarter 2024 Financial Results

November 6, 2024

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting

November 4, 2024

Kura Oncology to Report Third Quarter 2024 Financial Results

October 30, 2024

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)

October 23, 2024

Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors

October 22, 2024

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

September 29, 2024

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

September 16, 2024

Kura Oncology to Participate in Cantor Global Healthcare Conference

September 9, 2024

Kura Oncology Reports Second Quarter 2024 Financial Results

August 7, 2024

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

August 7, 2024

Kura Oncology to Report Second Quarter 2024 Financial Results

July 31, 2024

Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes

June 23, 2024

Kura Oncology to Participate in Jefferies Global Healthcare Conference

May 28, 2024

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

May 13, 2024

Kura Oncology Reports First Quarter 2024 Financial Results

May 1, 2024

Kura Oncology to Report First Quarter 2024 Financial Results

April 24, 2024

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

April 21, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

March 5, 2024

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

February 25, 2024

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

February 19, 2024

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

January 29, 2024

Kura Oncology Announces Oversubscribed $150 Million Private Placement

January 23, 2024

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

December 7, 2023

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

November 27, 2023

Kura Oncology Reports Third Quarter 2023 Financial Results

November 1, 2023

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

November 1, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.